| Gene symbol | TNFRSF17 | Synonyms | BCM, BCMA, CD269, TNFRSF13A | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p13.13 | dbXrefs | |
| Description | TNF receptor superfamily member 17 | ||||
| GTO ID | GTC3425 |
| Trial ID | NCT05836896 |
| Disease | Multiple Myeloma | Neoplasm | Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
| Altered gene | BCMA |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | MDC-CAR-BCMA001 |
| Phase | Phase1 |
| Recruitment status | Not Recruiting |
| Title | A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies |
| Year | 2023 |
| Country | Germany |
| Company sponsor | Technische Universität Dresden |
| Other ID(s) | TUD-BCMACA-078 |
| Cohort 1 | |||||||||
|
|||||||||